• Michał T Pochopień, CherneyDavid Z IDZI, Kerstin Folkerts, Pierre Levy, Aurélie Millier, Stephen Morris, Prabir Roy-Chaudhury, Sean D Sullivan, and Paul Mernagh.
• Creativ-Ceutical, Paris, France, Kraków, Poland. Email: michal.pochopien@creativ-ceutical.com.
• Am J Manag Care. 2021 Dec 1; 27 (20 Suppl): S375-S382.

BackgroundChronic kidney disease (CKD) is a progressive and irreversible disease often associated with type 2 diabetes (T2D). CKD is associated with an elevated risk of cardiovascular (CV) events, increased mortality, and diminished quality of life. Finerenone is a new treatment for patients with CKD and T2D that delays CKD progression and reduces CV complications.ObjectiveTo describe the approach and structure of a costeffectiveness model for finerenone for patients with CKD and T2D and compare it with existing economic models in CKD.MethodsA de novo cost-effectiveness model (FINE-CKD model), reflective of FIDELIO-DKD results, was developed for finerenone. The FINE-CKD model was designed and implemented in accordance with published guidance on modeling and was developed with input from economic and clinical experts. The final model approach was evaluated against existing modeling structures in CKD identified through a systematic literature review.Results And ConclusionsThe FINE-CKD model structure follows recommended modeling guidelines and has been designed in accordance with the best practices of modeling in CKD, while also incorporating important features of the FIDELIO-DKD design and results. The approach is consistent with the published literature, ensuring transparency and minimizing uncertainty that can arise from unnecessary complexity. The FINE-CKD model allows for reliable assessment of benefits and costs related to the use of finerenone in patients with CKD and T2D, and it is a reliable assessment of cost-effectiveness.

12 keywords...

hide…